Work

A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.4021

Authors: Kim Anna Reiss, Rosemarie Mick, Ursina R. Teitelbaum, Mark H. O'Hara, Charles John Schneider, Ryan Campbell Massa, Thomas Benjamin Karasic, Chioma Onyiah, Mary Kate Gosselin, Alyssa Donze, Susan M. Domchek, Robert H. Vonderheide

Institutions: Abramson Cancer Center, University of Pennsylvania, Hospital of the University of Pennsylvania

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281959511

Cites:

Cited by: 3

Related to: 10